Ipamorelin is a synthetic pentapeptide that stimulates growth hormone (GH) release from the pituitary gland with notable selectivity—preclinical research shows it does so without significantly raising cortisol or ACTH. At TelosRX, peptide protocols are evaluated and prescribed asynchronously, subject to medical approval by a licensed provider.
First described in published research in the late 1990s, ipamorelin quickly distinguished itself from earlier growth hormone secretagogues (GHSRPs) by its narrow hormonal profile. Where GHRP-6 and GHRP-2 spike cortisol and ACTH alongside GH, ipamorelin appears to trigger GH release without pulling those other hormones along.
Ipamorelin is not FDA-approved. It is a research peptide prepared by licensed compounding pharmacies and available subject to provider evaluation. This article reviews what published studies have actually found.
What Is Ipamorelin? Mechanism and Target
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide that acts on the growth hormone secretagogue receptor (GHSR-1a)—the same receptor targeted by ghrelin, the stomach-derived hunger and GH-signaling hormone. Binding GHSR-1a in the hypothalamus and pituitary triggers a pulse of GH release.
What separates ipamorelin from other GHSRPs is binding selectivity. At standard doses, it does not meaningfully engage receptors for ACTH, cortisol, or prolactin. This selectivity is the central claim of the foundational 1998 research that defined the compound's profile.
Finding 1: Ipamorelin as the First Selective GH Secretagogue
The defining ipamorelin study was published by Raun and colleagues in the European Journal of Endocrinology (1998). The team compared ipamorelin to GHRP-6 and GHRP-2 across in vitro cell assays and in vivo models in rats and conscious swine (PubMed PMID 9849822).
Key reported findings:
- Ipamorelin released GH from rat pituitary cells with potency and efficacy similar to GHRP-6
- In conscious swine, ipamorelin produced GH peaks comparable to GHRP-6 and GHRP-2
- Critically: GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol at standard doses. Ipamorelin did not—even at doses more than 200 times higher than the GH-release ED50
- The authors concluded ipamorelin was the first GHRP-receptor agonist with GH selectivity comparable to endogenous GHRH (the body's own growth hormone-releasing hormone)
This selectivity profile is why ipamorelin attracted sustained research interest as a potentially better-tolerated alternative to its predecessors.
Finding 2: GH Pulse Characteristics
A human pharmacology study (referenced across subsequent reviews, including work cited in Examine's ipamorelin overview) enrolled healthy volunteers across multiple dose levels and reported that ipamorelin induced biologically relevant GH secretion with peak plasma GH arriving within approximately one hour of administration. The GH pulse followed a defined peak-and-return pattern rather than prolonged elevation.
Human clinical data specific to ipamorelin alone remains limited. Most downstream research has combined ipamorelin with GHRH analogs like CJC-1295, which prolongs and amplifies the GH pulse via a different receptor pathway. The CJC-1295 and Ipamorelin stack research article covers that combination in detail.
Finding 3: Body Composition Research
Growth hormone plays a documented role in body composition—specifically in supporting lean mass and reducing adiposity through lipolysis and protein synthesis signaling. Preclinical research on ipamorelin and related GHSRPs has explored whether GH stimulation translates to meaningful body composition effects.
Animal studies have shown that sustained GH secretagogue use can reduce adiposity and support lean tissue in aged rodents. However, these findings come from animal models and cannot be directly extrapolated to human outcomes. No large, randomized controlled human trial has specifically tested ipamorelin as a standalone body composition intervention.
Research on GH secretagogues broadly suggests body composition effects are likely modest and most pronounced in combination with resistance training and adequate dietary protein. Ipamorelin is studied as a supportive tool within a broader protocol, not a standalone intervention.
Finding 4: Sleep and Recovery Research
GH secretion is highest during slow-wave (deep) sleep. GH secretagogues including ipamorelin are studied for their potential to amplify this nighttime GH pulse when administered before bed. Preclinical research has associated GHSR-1a agonism with deeper sleep stages and increased GH amplitude during sleep cycles.
Anecdotal reports from clinical use describe improved sleep depth as one of the earliest perceived effects of ipamorelin-containing protocols. No controlled human trials on sleep-specific endpoints for standalone ipamorelin have been published. These reports are mechanistically plausible but do not constitute clinical evidence.
Ipamorelin vs. Other Growth Hormone Peptides
| Peptide | Receptor Target | Cortisol/ACTH Effect | GH Pulse Duration | Evidence Level |
|---|---|---|---|---|
| Ipamorelin | GHSR-1a (ghrelin receptor) | Minimal at standard doses | Short pulse (~1–2 hr) | Preclinical + limited human |
| GHRP-6 | GHSR-1a | Significant increase | Short pulse (~1–2 hr) | Preclinical + human |
| GHRP-2 | GHSR-1a (higher potency) | Moderate increase | Short pulse | Preclinical + human |
| Sermorelin | GHRH receptor | Minimal | Moderate pulse | Human trials (historical FDA approval) |
| CJC-1295 | GHRH receptor (long-acting) | Minimal | Prolonged elevation | Human trials |
None of these compounds is FDA-approved for the indications most commonly discussed in peptide research contexts. All require provider evaluation for compounded use.
If you're exploring peptide options, TelosRX's asynchronous evaluation process lets a licensed provider review your health history and determine whether ipamorelin or a combination protocol fits your situation. For related growth hormone peptide research, see the TelosRX Sermorelin research guide.
Safety Profile: What the Research Shows
Ipamorelin's safety profile in research settings has generally been favorable relative to other GHSRPs, primarily because of its cortisol/ACTH selectivity. The absence of significant cortisol elevation at typical doses reduces risks associated with chronic cortisol excess.
Reported side effects in preclinical and observational contexts:
- Transient water retention — a common GH-related effect
- Mild injection site reactions — redness, minor irritation
- Headache — typically associated with GH-mediated fluid shifts
- Tingling (paresthesia) — common across GH-elevating peptide protocols
Long-term human safety data for ipamorelin is limited. Concerns raised in the broader GH secretagogue literature include potential for insulin resistance with prolonged GH elevation and theoretical risk of promoting growth in existing neoplastic tissue. A full safety review with a licensed provider is appropriate before starting any GH secretagogue protocol.
Frequently Asked Questions
What does ipamorelin do in the body?
Ipamorelin binds to the GHSR-1a (ghrelin receptor) in the hypothalamus and pituitary, triggering a pulse of growth hormone release. Unlike GHRP-6 and GHRP-2, preclinical research shows ipamorelin achieves this without significantly raising cortisol or ACTH at standard doses—a selectivity that distinguishes it from earlier GH secretagogues.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved for any medical indication. It is a compounded research peptide available through licensed compounding pharmacies, subject to evaluation and a provider-issued prescription. Compounded ipamorelin is not an FDA-approved finished drug product.
How is ipamorelin different from CJC-1295?
Ipamorelin acts on the ghrelin receptor (GHSR-1a) to trigger GH release. CJC-1295 is a GHRH analog that amplifies the hypothalamic signal upstream, acting on a different receptor. They operate at different points in the GH axis and are often combined in protocols because their mechanisms complement each other.
What does the research show about ipamorelin and muscle growth?
Animal research on GH secretagogues suggests potential support for lean mass and reduced adiposity. No large-scale randomized controlled human trial has established ipamorelin as an effective standalone body composition intervention. Available evidence suggests modest effects, most likely meaningful in combination with resistance training and adequate nutrition.
How is ipamorelin administered?
Ipamorelin is typically administered via subcutaneous injection. Dosing protocol, frequency, and concentration are determined by a licensed provider based on individual health history and goals. Subject to medical approval; compounded ipamorelin requires a provider-issued prescription.
What are the side effects of ipamorelin?
Reported side effects include transient water retention, mild injection site reactions, headache, and tingling (paresthesia). These are common across GH-elevating peptide protocols. No serious adverse effects have been documented in available research, but long-term human safety data is limited. A thorough provider review is necessary before starting.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.